^
    Back
    Association details:
    Biomarker:GDF15 overexpression
    Cancer:Oral Cancer
    Regimen:TPF (5-fluorouracil + cisplatin + docetaxel)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Spandidos Publications
    Title:

    Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer

    Excerpt:
    Furthermore, the cT3/4N0M0 patients with high GDF15 expression benefited significantly from TPF induction chemotherapy, including overall survival (HR=0.233; P=0.02), disease‑free survival (HR=0.296; P=0.014), locoregional recurrence‑free survival (HR=0.347; P=0.035) and distant metastasis‑free survival (HR=0.212; P=0.013) rates.
    DOI:
    10.3892/ol.2018.8324
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Sci
    Title:

    Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression

    Published date:
    12/21/2021
    Excerpt:
    The results indicated that OSCC cells overexpressing GDF15 were sensitive to TPF through a caspase-9-dependent pathway both in vitro and in vivo....When OSCC cells with GDF15 overexpression were treated with the erbB2 phosphorylation inhibitor, CI-1033, cell proliferation and xenograft growth colony formation were significantly blocked (P < .05)....Thus, ErbB2 inhibitors could represent potential targeted drugs or an alternative therapy for OSCC patients with GDF15 overexpression.
    DOI:
    10.1111/cas.15218